EA201690271A1 - Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот - Google Patents

Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот

Info

Publication number
EA201690271A1
EA201690271A1 EA201690271A EA201690271A EA201690271A1 EA 201690271 A1 EA201690271 A1 EA 201690271A1 EA 201690271 A EA201690271 A EA 201690271A EA 201690271 A EA201690271 A EA 201690271A EA 201690271 A1 EA201690271 A1 EA 201690271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
expression
cells
eukaryot
constructions
methods
Prior art date
Application number
EA201690271A
Other languages
English (en)
Inventor
Кристель Эбишер-Гуми
Мартин Бертшингер
Пьер Моретти
Original Assignee
Гленмарк Фармасьютикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гленмарк Фармасьютикалс С.А. filed Critical Гленмарк Фармасьютикалс С.А.
Publication of EA201690271A1 publication Critical patent/EA201690271A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Abstract

Настоящее изобретение относится к экспрессируемой конструкции для экспрессии полипептидов в клетках-хозяевах с использованием альтернативного сплайсинга. Конструкцию для экспрессии можно применять для экспрессии полипептидов, таких как антитела, фрагменты антител и биспецифичные антитела, путем экспрессии продуктов генов, необходимых для экспрессии белка, в соотношении, обеспечивающем получение самых высоких титров или самого лучшего профиля качества продукта.
EA201690271A 2013-08-06 2014-08-05 Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот EA201690271A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13179375 2013-08-06
PCT/EP2014/066826 WO2015018832A1 (en) 2013-08-06 2014-08-05 Expression constructs and methods for expressing polypeptides in eukaryotic cells

Publications (1)

Publication Number Publication Date
EA201690271A1 true EA201690271A1 (ru) 2016-07-29

Family

ID=51300736

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690271A EA201690271A1 (ru) 2013-08-06 2014-08-05 Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот

Country Status (14)

Country Link
US (3) US20150056655A1 (ru)
EP (1) EP3030579A1 (ru)
JP (3) JP2016528896A (ru)
KR (2) KR102104581B1 (ru)
CN (1) CN105658665A (ru)
AU (2) AU2014304570B2 (ru)
BR (1) BR112016002319A2 (ru)
CA (1) CA2920574C (ru)
EA (1) EA201690271A1 (ru)
IL (2) IL243967A0 (ru)
MX (1) MX2016001678A (ru)
NZ (1) NZ717178A (ru)
SG (1) SG11201600736SA (ru)
WO (1) WO2015018832A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041004A1 (en) * 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
WO2020205604A1 (en) * 2019-03-29 2020-10-08 Salk Institute For Biological Studies High-efficiency reconstitution of rna molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
WO2005089285A2 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
US20090305343A1 (en) * 2006-05-16 2009-12-10 Millegen Method For Expressing Polypeptides In Eukaryotic Cells Using Alternative Splicing
JP5875009B2 (ja) * 2010-06-01 2016-03-02 国立大学法人京都大学 哺乳類生物における選択的スプライシングの発現プロファイルおよび制御機構を明らかにするトランスジェニックレポーターシステム

Also Published As

Publication number Publication date
EP3030579A1 (en) 2016-06-15
AU2019236586B2 (en) 2020-12-03
CA2920574C (en) 2021-03-16
CA2920574A1 (en) 2015-02-12
US20150056655A1 (en) 2015-02-26
KR20200044154A (ko) 2020-04-28
JP2020202840A (ja) 2020-12-24
KR20160035084A (ko) 2016-03-30
AU2014304570B2 (en) 2019-07-25
AU2019236586A1 (en) 2019-10-10
KR102104581B1 (ko) 2020-06-02
SG11201600736SA (en) 2016-02-26
CN105658665A (zh) 2016-06-08
NZ717178A (en) 2022-02-25
MX2016001678A (es) 2016-10-28
JP2016528896A (ja) 2016-09-23
BR112016002319A2 (pt) 2017-09-12
JP2022177131A (ja) 2022-11-30
IL243967A0 (en) 2016-04-21
US20170253671A1 (en) 2017-09-07
IL269252A (en) 2019-11-28
WO2015018832A1 (en) 2015-02-12
AU2014304570A1 (en) 2016-03-10
US20200172634A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
ZA201902383B (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
WO2014165082A3 (en) Antibodies and methods of detection
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2018013738A (es) Anticuerpos que comprenden dominios constantes quimericos.
PE20171383A1 (es) Receptores de antigeno quimericos anti-dll3 y metodos de uso
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201691027A1 (ru) Модуляторы aplnr и их применение
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
MX2016016886A (es) Anticuerpos anti-axl.
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201791424A1 (ru) Получение белка
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
EA201992206A1 (ru) Моноклональное антитело к pd-l1
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
SG10201807572PA (en) Robust antibody purification
EA201690942A1 (ru) Антитела к ccl17